Study provides a potential game-changer in assessing treatment response in pancreatic cancer patients

The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030.

Related Keywords

Nuno Couto ,Bruno Costa Silva ,Emily Henderson ,Champalimaud Clinical Centre ,Champalimaud Foundation ,Systems Oncology Lab At Champalimaud Research ,Systems Oncology Lab ,Champalimaud Research ,Cancer ,Pancreatic Cancer ,Adenocarcinoma ,Ntigen ,Biomarker ,Flood ,Fell ,Chemotherapy ,It ,Maging ,Immune System ,Alignant ,Ncology ,Protein ,Surgery ,